CHMA News and Press, Chiasma Inc. From 03/08/19

On track for top-line data from Phase 3 CHIASMA OPTIMAL trial of octreotide capsules, conditionally trade-named MYCAPSSA ®, expected in Q3 2019 Assuming positive OPTIMAL data , NDA submission expected by year-end 2019 WALTHAM, Mass., March 08, 2019 (GLOBE NEWSWIRE) -- Chia...

Chiasma (NASDAQ: CHMA ) initiated with Overweight rating and $18 (208% upside) price target. Shares up  3%  premarket. More news on: Chiasma, Mylan Inc, Teva Pharmaceutical Industries Limited, Healthcare stocks news, Stocks on the move, Read more ...

Thinly traded micro cap Chiasma ( CHMA +14.6% ) is up on almost a 6x surge in volume, albeit on turnover of only 374K shares. The stock has rallied  36%  since last week. More news on: Chiasma, Healthcare stocks news, Stocks on the move, Read more ...

WALTHAM, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced that Mark Fitzpatrick, Chief Executive Officer and William Ludlam, MD...

WALTHAM, Mass., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases today announced its support for the patient and research communities in recognition of...

Company continues to advance its novel octreotide capsules candidate through Phase 3 clinical trials in the U.S. and E.U. WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of pat...